Popular Trials
Monoclonal Antibodies
RBS-001 vs Eylea for Age-Related Macular Degeneration
This trial aims to show that two different treatments, RBS-001 and Eylea, are equally effective and safe in treating a specific eye condition called Neovascular age-related macular degeneration
Anti-VEGF Therapy
Axitinib Implant for Age-Related Macular Degeneration
This trial is testing a small device placed in the eye that releases medication for patients with a severe form of AMD. The medication helps stop abnormal blood vessel growth in the eye, potentially preventing further vision loss. This approach has significantly improved treatment for this condition in recent years.
Popular Filters
Trials for Macular Degeneration Patients
Gene Therapy
Gene Therapy (ADVM-022) for Age-Related Macular Degeneration
This trial is testing a gene therapy product, ADVM-022, for the treatment of neovascular or wet age-related macular degeneration (nAMD). The product is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
Monoclonal Antibodies
SUSVIMO for Age-Related Macular Degeneration
This trial will assess the response to treatment with SUSVIMO given every 24 weeks in patients with nAMD who have been previously treated with anti-VEGF agents. A substudy will evaluate the impact of SUSVIMO on corneal endothelial cells.
Vascular Endothelial Growth Factor (VEGF) Inhibitor
OPT-302 + Aflibercept for Age-Related Macular Degeneration
This trial will compare a new treatment to a sham (fake) treatment in order to see if the new treatment is effective. The primary efficacy will be determined at Week 52, meaning that's how long the trial will last.
Gene Therapy
RGX-314 for Age-Related Macular Degeneration
This trial will evaluate the safety & efficacy of RGX-314 over 5yrs in people who have received it in one eye in a previous study. A substudy will look at its safety & immunogenicity in the fellow eye.
Trials for Age-Related Macular Degeneration Patients
Complement Inhibitor
Iptacopan for Age-Related Macular Degeneration
This trial tests if Iptacopan capsules can prevent worsening of early or intermediate AMD in people who already have severe AMD in one eye. The goal is to see if the medication can protect eye cells and slow down vision loss.
Gene Therapy
RGX-314 Gene Therapy for Age-Related Macular Degeneration
This trial is evaluating a potential new treatment for a disease that causes vision loss. The current standard of care for this disease requires life-long, repeated injections to maintain efficacy, but this new treatment would only require a single injection.
Gene Therapy
RGX-314 for Age-Related Macular Degeneration
This trial will evaluate the safety & efficacy of RGX-314 over 5yrs in people who have received it in one eye in a previous study. A substudy will look at its safety & immunogenicity in the fellow eye.
Phase 3 Trials
Vascular Endothelial Growth Factor (VEGF) Inhibitor
OPT-302 + Aflibercept for Age-Related Macular Degeneration
This trial will compare a new treatment to a sham (fake) treatment in order to see if the new treatment is effective. The primary efficacy will be determined at Week 52, meaning that's how long the trial will last.
Anti-VEGF
Aflibercept for Age-Related Macular Degeneration and Diabetic Macular Edema
This trial is testing a new drug called aflibercept 8 mg on people with nAMD and DME who have already used other medications. The goal is to see how safe and effective the drug
Trials With No Placebo
Gene Therapy
Gene Therapy (ADVM-022) for Age-Related Macular Degeneration
This trial is testing a gene therapy product, ADVM-022, for the treatment of neovascular or wet age-related macular degeneration (nAMD). The product is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
Monoclonal Antibodies
SUSVIMO for Age-Related Macular Degeneration
This trial will assess the response to treatment with SUSVIMO given every 24 weeks in patients with nAMD who have been previously treated with anti-VEGF agents. A substudy will evaluate the impact of SUSVIMO on corneal endothelial cells.
Gene Therapy
RGX-314 Gene Therapy for Age-Related Macular Degeneration
This trial is evaluating a potential new treatment for a disease that causes vision loss. The current standard of care for this disease requires life-long, repeated injections to maintain efficacy, but this new treatment would only require a single injection.
Gene Therapy
RGX-314 for Age-Related Macular Degeneration
This trial will evaluate the safety & efficacy of RGX-314 over 5yrs in people who have received it in one eye in a previous study. A substudy will look at its safety & immunogenicity in the fellow eye.
View More Related Trials
Frequently Asked Questions
Introduction to wet macular degeneration
What are the top hospitals conducting wet macular degeneration research?
In the battle against wet macular degeneration, several top hospitals are spearheading innovative clinical trials to combat this progressive eye condition. Located in Reno, Sierra Eye Associates is at the forefront with five active trials and a total of 12 studies dedicated to wet macular degeneration. Their commitment began in 2018 when they recorded their first trial, aiming to improve treatments for this complex disease. Retina Consultants of Texas, based in The Woodlands, is also actively engaged in finding new solutions with four ongoing trials and a history of eight conducted studies since joining the fight against wet macular degeneration in 2018.
Meanwhile, Boston's Ophthalmic Consultants of Boston has been contributing significantly with three active clinical trials and a noteworthy record of nine previous investigations into this condition since embarking on their research journey back in 2017. Charles Retina Institute located in Germantown shares similar dedication as it currently conducts three ongoing clinical tests while having previously completed six experiments since initiating its pioneering investigation into wet macular degeneration just three years ago.
Even Santa Barbara plays an important role through its local location where two active clinical trials aimed at combating wet macular degeneration are underway; although relatively newer players compared to others on our list having only begun their research efforts last year(2019), every contribution counts toward potential breakthroughs that can positively impact countless lives affected by this visually impairing condition.
These leading hospitals demonstrate unwavering commitment to advancing medical knowledge and treatment options for those diagnosed with wet macular degeneration. Together, they represent hope for patients worldwide as they strive towards uncovering effective therapies that bring brighter tomorrows for individuals facing visual challenges caused by this progressive eye disease.
Which are the best cities for wet macular degeneration clinical trials?
When it comes to wet macular degeneration clinical trials, a few cities emerge as leading hubs for research and development. Phoenix, Arizona takes the lead with 13 active trials investigating treatments like ADVM-022, RGX-314, and CLS-AX. Austin, Texas follows closely with 12 ongoing studies focused on innovative approaches such as Faricimab and Aflibercept High Dose VEGF Trap-Eye. In Reno, Nevada and Philadelphia, Pennsylvania, both cities boast 11 active trials exploring promising interventions like RGX-314 and Faricimab. Lastly, Boston in Massachusetts showcases its dedication to finding effective treatments through 10 active trials targeting wet macular degeneration. These cities provide individuals affected by this condition access to cutting-edge clinical research that holds promise for improved outcomes in the future.
Which are the top treatments for wet macular degeneration being explored in clinical trials?
Exciting advancements are being made in the realm of wet macular degeneration, with several top treatments currently under investigation through clinical trials. Among these potential game-changers is bevacizumab, which has caught the attention with its involvement in one active and four all-time trials dedicated to wet macular degeneration since 2018. Another contender making waves is RGX-314, also participating in one ongoing trial and two past trials for this condition since its introduction in 2019. Additionally, faricimab shows promise with one current and three historical wet macular degeneration trials since its debut in 2019. Let's not overlook the newest entrants: RGX-314 Dose 2 and doxycycline hyclate both show potential as they make their mark on the scene by joining a single active trial each for this debilitating eye disease starting from 2020 onwards. These pioneering treatments hold hope for a brighter future for individuals battling wet macular degeneration around the world.
What are the most recent clinical trials for wet macular degeneration?
Recent advancements in clinical trials offer hope for individuals with wet macular degeneration. One of the promising studies is investigating Dose 1, which has progressed to Phase 2 after successful Phase 1 results. Additionally, CLS-AX at a dosage of 1.0 mg is being evaluated in Phase 2 trials as a potential treatment option. Another trial focuses on the efficacy of Ranibizumab for wet macular degeneration and has reached Phase 4 after previous phases showed promise. Furthermore, AIV007 Dose 1 and Part A are undergoing Phase 1 evaluations to assess their effectiveness against this debilitating condition. These ongoing trials bring optimism for improved treatments and outcomes for those affected by wet macular degeneration.
What wet macular degeneration clinical trials were recently completed?
Recent advancements in clinical trials for wet macular degeneration have yielded promising results, offering hope to those affected by this debilitating condition. Notably, Sandoz completed a trial investigating the efficacy of SOK583A1 in May 2022, while a previous trial testing a higher dosage of SOK583A1 (40 mg/mL) wrapped up in May 2021. Additionally, AsclepiX Therapeutics concluded their research on AXT107 0.1 mg in February 2021. These trials signify significant progress and underscore the commitment of various sponsors such as Novartis Pharmaceuticals, Clearside Biomedical, Unity Biotechnology, Samsung Bioepis Co., Ltd., Aerie Pharmaceuticals, and Hoffmann-La Roche to seek innovative solutions against wet macular degeneration.